Development of CRISPR strategies to treat inherited retinal diseases

A single genetic typo in the *Ush2a* gene can sentence a young person to blindness, and this research team has already corrected that exact error in mice using CRISPR gene editing. This matters because inherited retinal diseases are a leading cause of untreatable blindness in young people, and current gene therapies are often useless—they rely on delivery vehicles called AAV vectors that are too small to carry the large genes needed for many forms of the condition. The researchers have built a new delivery system using DNA minicircles that sidesteps that size limit, potentially making gene therapy possible for a much wider range of retinal disorders. If this succeeds, it could transform how we treat inherited blindness. The team runs clinical trials, so they are positioned to move findings from the lab bench directly into patients. But the project is fundamentally curiosity-driven: it asks how CRISPR corrects genes inside retinal cells and how ectopic gene expression is regulated. That basic understanding is essential—without it, attempts to translate the tool into a reliable therapy risk failure. Similar fundamental work on CRISPR’s mechanisms in other tissues has already spawned clinical trials for blood disorders and cancers.